R
Robby A. Petros
Researcher at University of North Texas
Publications - 28
Citations - 4277
Robby A. Petros is an academic researcher from University of North Texas. The author has contributed to research in topics: Systemic acquired resistance & Particle. The author has an hindex of 11, co-authored 28 publications receiving 3874 citations. Previous affiliations of Robby A. Petros include Texas Woman's University & Columbia University.
Papers
More filters
Journal ArticleDOI
Strategies in the design of nanoparticles for therapeutic applications
TL;DR: This Review focuses on recent progress important for the rational design of such nanoparticles and discusses the challenges to realizing the potential of nanoparticles.
Journal ArticleDOI
The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies.
TL;DR: The data clearly reveal that one must be careful in making claims of "lack of toxicity" when a targeting molecule is used on nanoparticles and also raise concerns for unanticipated off-target effects when one is designing targeted chemotherapy nanodelivery agents.
Journal ArticleDOI
An abietane diterpenoid is a potent activator of systemic acquired resistance.
Ratnesh Chaturvedi,Barney J. Venables,Robby A. Petros,Vamsi J. Nalam,Maoyin Li,Maoyin Li,Xuemin Wang,Xuemin Wang,Larry J. Takemoto,Jyoti Shah +9 more
TL;DR: Dehydroabietinal (DA), an abietane diterpenoid, is an activator of systemic acquired resistance (SAR), which is an inducible defense mechanism that is activated in the distal, non-colonized, organs of a plant that has experienced a local foliar infection.
Journal ArticleDOI
Signaling by small metabolites in systemic acquired resistance
TL;DR: The role of additional small metabolites in SAR signaling, including methyl salicylate, the abietane diterpenoid dehydroabietinal, the lysine catabolite pipecolic acid, and the relationship between them and SA signaling in SAR are summarized.
Journal ArticleDOI
Reductively labile PRINT particles for the delivery of doxorubicin to HeLa cells.
TL;DR: A Trojan horse PRINT particle composition was developed that incorporates a reductively labile cross-linker to achieve activated release of doxorubicin in vitro and was found to be highly proficient at killing HeLa cells in vitro.